ESR1 and breast neoplasm: Tamoxifen is the first accredited selective ERα modulator for breast cancer therapy and has demonstrated efficacy in reducing recurrence rates and improving the prognosis of ERα-positive breast tumors (Ariazi et al., 2006; Early Breast Cancer Trialists’ Collaborative Group, 2011).